TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine patients without aura who fulfill criteria in the international classification of headaches. This does not apply to healthy volunteers.~* 18-60 years.~* 50-90 kg.~* Women of childbearing potential must use adequate contraception.~Exclusion Criteria:~* Headache less than 48 hours before the tests start~* All primary headaches, except migraine without aura for migraine patients, according to international classification of headache~* Daily consumption of drugs of any kind other than oral contraceptives~* Pregnant or nursing women.~* Cardiovascular disease of any kind, including cerebrovascular diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Maxipost (Type: ACTIVE_COMPARATOR): None
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Initial Combination With Pioglitazone Study (0431-064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Patients ≥18 years old with Type 2 Diabetes Mellitus (a specific type of diabetes)~General Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 4 months~* Patient was on \>4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
- 2 (Type: ACTIVE_COMPARATOR): sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected children~* Resident in Cape Town~* Informed consent obtainable~* weight \> 2.5kg~* Access to transport~* HAART use for not less than 2 months but not more than 12 months with no significant demonstrated toxicity and good adherence~Exclusion Criteria:~* Chronic diarrhoea~* Current use of INH prophylaxis~* Prior hypersensitivity to INH prior history of allergy to sulphur drugs~* Prior history of allergy to sulphur drugs~* Severe anaemia (haemoglobin less than 7 gm/dl)~* Neutropenia (absoloute neutrophil count less than 400 cells)~* Thrombocytopenia (platelet count \< 50 000/uL)~* Non-reversible renal failure~* Clinical hepatitis~* Exposure to household TB contact, requiring INH prophylaxis

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Isoniazid preventive therapy (Type: EXPERIMENTAL): HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
- Placebo (Type: PLACEBO_COMPARATOR): HIV infected children living in a high TB prevalence area receive placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Effect on Klinefelter Syndrome Motor Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Karyotype diagnosis of Klinefelter syndrome~* Chronological age of 4-12 years~* No treatment with androgen in the past year~Exclusion Criteria:~* Major liver, kidney or other systemic disease~* Variant karyotypes including 47,XYY males~* Evidence of spontaneous onset of puberty, defined as testicular size \> 4ml

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Oxandrolone (Type: ACTIVE_COMPARATOR): Androgen oxandrolone: Oxandrolone, 0.6 \> mg/kg/day, orally, for 2 years.
- Placebo (Type: PLACEBO_COMPARATOR): An inactive substance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minimum Effective Volume of Local Anesthetic for Peribulbar Block.Does it Differ With the Eyeball Axial Length?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* we allocated adult patients aged 40-70 years, of both gender, American Society of Anesthesiologists (ASA) II - III, listed for elective cataract extraction using phaco emulsification technique with intraocular lens implantation surgery.~Exclusion Criteria:~* Patients known to have any systemic contraindications (as severe hypertension) or allergy to the local anesthetic, those who refused local anesthesia, high myopes (axial length \> 26 mm), patients with a single eye, those with complicated vitreous hemorrhage, ocular infection, or associated glaucoma have been excluded.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group 1(22-24 mm) (Type: EXPERIMENTAL): Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.
- Group 2(24.1-26 mm) (Type: EXPERIMENTAL): Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria include:~1. Males and females ≥18 years of age~2. Participants with IDA defined as having:~   1. Hemoglobin \<10.0 g/deciliter (dL)~  2. Transferrin saturation \<20%~3. Participants who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used~4. Female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study~Key Exclusion Criteria include:~1. History of allergy to IV iron~2. Allergy to two or more classes of drugs~3. Participants on dialysis or with an estimated glomerular filtration rate \<30 mL/minute/1.73 m\^2~4. Female participants who are pregnant, intend to become pregnant, are breastfeeding, within 2 weeks postpartum, or have a positive serum/urine pregnancy test~5. Hemoglobin ≤7.0 g/dL~6. Serum ferritin \>600 nanograms/mL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: EXPERIMENTAL): Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters \[mL\]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Different Prefrontal Areas in Visual Metacognition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* right-handed~* adults 18-40~* with normal or corrected-to-normal vision~Exclusion Criteria:~* history of seizures~* family history of epilepsy~* stroke~* severe headaches~* metal anywhere in the head (excluding the mouth)~* cardiac pacemakers~* current use of medication for neurological or psychiatric conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Adult Volunteers (Type: EXPERIMENTAL): The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be ≥18 years of age at the time of anticoagulation initiation~* Have diagnoses of type 2 diabetes and Non-valvular atrial fibrillation (NVAF)~* Have no record of prior oral anticoagulant (OAC) use in the prior 12-months~* Newly initiated on Rivaroxaban or Warfarin (index date)~* Have ≥12-months of electronic health record (EHR) activity prior to the index date and received care documented in the EHR database from at least one provider in the 12-months prior~Exclusion Criteria:~* Evidence of valvular heart disease defined as any rheumatic heart disease, mitral stenosis or mitral valve repair/replacement~* Pregnancy~* Use of rivaroxaban doses other than 15 mg once daily or 20 mg once daily or the presence of other indication(s) for OAC use~* Any prior OAC utilization per written prescription or self-report at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: None): Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban
- Group B (Type: None): Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Subjects diagnosed with T2DM and on unchanged metformin treatment at the maximum tolerated dose (at least 1000 mg/day and up to 3000 mg/day) for at least 90 days prior to screening~* HbA1c 7.5 - 10.5% (53 mmol/mol - 91 mmol/mol) (both inclusive)~* Body Mass Index (BMI) equal to or above 20 kg/m\^2~Exclusion Criteria:~* Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods. (Adequate contraceptive measures as required by local law or practice)~* Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days prior to screening. Exception is short-term treatment (equal to or below 7 days in total) with insulin in connection with intercurrent illness~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Screening calcitonin value equal to or above 50 ng/L~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)~* Impaired liver function, defined as alanine aminotransferase (ALAT) equal to or above 2.5 times upper normal limit (UNL)~* Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m\^2 per Modification of Diet in Renal Disease (MDRD) formula~* Any episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack (TIA) or other significant cardiovascular event as judged by the investigator within 90 days prior to screening~* Heart failure, New York Heart Association (NYHA) class IV~* Uncontrolled hypertension (defined as systolic blood pressure equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg)~* Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin + liraglutide 1.8 mg (Type: EXPERIMENTAL): None
- Metformin + lixisenatide 20 microg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cluster Headache Cortivazol Injection (CHCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient age, man or woman whose age is between 18 and 65 included~* patient who signed a free express and informed consent~* patient with cluster headache, episodic or chronic according to the criteria of International Headache Society (ICHD-II)~* patient with more than two episodes of CH per day~* patient with a normal medical examination~Exclusion Criteria:~* patient not affiliated with a social security scheme (or beneficiary entitled)~* patient with another diagnosis ICHD-II,and being unable to differentiate CH attacks from its other cranial pain~* patient of CH having started his episodic active period more than 30 days ago~* patient with a contra-indication to verapamil~* patient with a known allergy to cortivazol~* patient with anticoagulant therapy or having a bleeding disorder~* patient unable to complete the schedule crisis~* patient non-compliant or unable to follow the research protocol~* women without contraception, pregnant, or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): subcutaneous injection of Cortivazol ALTIM, 3,375mg
- 2 (Type: PLACEBO_COMPARATOR): PROAMP, subcutaneous serum physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participation in the GHLIQUID-1517 trial~* Patients with SGA (small for gestational age) short stature that are still growing~Exclusion Criteria:~* Known or suspected allergy to study product(s) or related products~* Diabetes Mellitus~* Patients with malignant tumor(s)~* Pregnant or likely to get pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norditropin® (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neck Cooling as a Non-Invasive Method to Lower Brain Temperature in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18-65 years~Exclusion Criteria:~* Pregnancy~* Contraindications to MRI (e.g. claustrophobia, metallic implants, etc.)~* Signs of ulcerations, burns, hives or rash where the neck wrap is applied~* History of Raynaud's disease, venous or arterial occlusive disease (e.g. carotid stenosis), cryoprecipitation disorders (e.g. cryoglobulinemia) and pernio (also known as chilblains)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cold circulated water (Type: EXPERIMENTAL): Cold water circulated through an adhesive wrap applied to the front of the neck.
- Body-temperature circulated water (Type: ACTIVE_COMPARATOR): Body-temperature water circulated through an adhesive wrap applied to the front of the neck.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lutein in Retinitis Pigmentosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
None

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Heterozygous Familial Hypercholesterolemia (HeFH):~-Completed Study 20120123 (NCT02392559) while still on assigned investigational product and did not experience a treatment-related serious adverse event~Homozygous Familial Hypercholesterolemia (HoFH):~* Male or female, ≥ 10 to ≤ 17 years of age at time of enrollment~* Diagnosis of HoFH~* On a low-fat diet and receiving background lipid-lowering therapy~* Lipid-lowering therapy unchanged for ≥ 4 weeks prior to LDL-C screening; fibrates must be stable for at least 6 weeks prior to screening.~* Fasting LDL-C at screening ≥ 130 mg/dL (3.4 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~-Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s); except Study 20120123~HoFH:~* Moderate to severe renal dysfunction~* Active liver disease or hepatic dysfunction,~* Creatine kinase \> 3 times the upper limit of normal (ULN) at screening

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Male or female at least 18 years of age~* Patients who are to initiate Exenatide treatment for type 2 diabetes at baseline, following their treating physicians' advice~* Patients, who in the opinion of the treating physicians, comply with all the recommendations stated in the relevant product information~Exclusion Criteria:~* Are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug~* Are pregnant or have intentions of becoming pregnant within the duration of the study~* Contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group1:Type 2 diabetic patients treated with Exenatide therapy (Type: None): Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete